NIAID Archives
Exploiting viral vulnerabilities
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
Study details early events of inflammatory response
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
VUMC begins study of second COVID-19 vaccine
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
Preserving gut mucus architecture
Oct. 20, 2020—A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.
Early steps in reovirus replication
Oct. 6, 2020—Conformational change in a reovirus surface protein modulate the virus’s attachment to host cells, Vanderbilt researchers have found.
Rational vaccine design
Sep. 22, 2020—Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.
Probing pathogen antibiotic resistance
Sep. 17, 2020—Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.
Risk marker for repeat sinus surgery
Aug. 11, 2020—An inflammatory factor in mucus could be a biomarker of treatment-resistant chronic sinusitis used to determine which patients are at risk for repeat sinus surgery.
The importance of estrogen cycles
Aug. 6, 2020—Deborah Lannigan and colleagues identify a key regulator of the estrogen receptor and suggest that its downregulation by oral contraceptives may increase oxidative stress and DNA damage, a common cause of cancer.
Stomach bug hit-and-run
Jul. 23, 2020—The H. pylori machinery that “injects” an oncoprotein into stomach cells contributes to the development of gastric cancer, Vanderbilt researchers demonstrate.
Cellular antiviral defenses
Jul. 23, 2020—A cellular RNA quality control mechanism was known to restrict replication of RNA viruses. Vanderbilt researchers have discovered it is also antiviral against DNA viruses.
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.
